Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
89.82
-0.96 (-1.06%)
At close: Oct 12, 2026, 4:00 PM EDT
89.08
-0.74 (-0.83%)
After-hours: Oct 12, 2026, 4:05 PM EDT
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 414 employees as of December 31, 2025. The number of employees increased by 131 or 46.29% compared to the previous year. That makes Rhythm Pharmaceuticals the 21,476th largest employer in the world and 2,827th in the United States.
Employees
414
Change (1Y)
131
Growth (1Y)
46.29%
Revenue / Employee
$579,512
Profits / Employee
-$507,783
Market Cap
6.18B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 414 | 131 | 46.29% |
| Dec 31, 2024 | 283 | 57 | 25.22% |
| Dec 31, 2023 | 226 | 49 | 27.68% |
| Dec 31, 2022 | 177 | 37 | 26.43% |
| Dec 31, 2021 | 140 | 50 | 55.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Iovance Biotherapeutics | 975 |
| Mirum Pharmaceuticals | 433 |
| Immunovant | 315 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
| Erasca | 103 |
| Oruka Therapeutics | 68 |
RYTM News
- 20 days ago - Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity - GlobeNewsWire
- 27 days ago - Rhythm Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - GlobeNewsWire
- 4 weeks ago - Rhythm Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Rhythm Pharmaceuticals Slides: Corporate presentation - Filings
- 7 weeks ago - Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - GlobeNewsWire
- 1 month ago - Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts